Dear Sir/Ma,

At AEyeCARE, we have developed ASPIRE—an AI-powered application designed to enhance the diagnosis and management of Severe Malaria in children. Integrated into an Android-powered handheld retinal camera that does fundoscopy, ASPIRE detects a clinical biomarker (malaria retinopathy) for Cerebral Malaria within the first hour of arrival of the child at a healthcare facility. With results available in approximately one minute, it provides clinicians with real-time, bedside insights indicative of processes ongoing in the child's brain, supporting swift and accurate decision-making.

The World Health Organization (WHO) recognizes that one of the causes of misdiagnosis in Severe Malaria is the inability to do fundoscopy. ASPIRE is providing AI-enabled fundoscopy. 

ASPIRE addresses critical challenges in Severe Malaria management by:

Improving Diagnosis Accuracy: Reducing the current 23% misdiagnosis rate to less than 1%.

Enhancing Triage and Treatment: Enabling timely interventions that reduce delays in care and enabled Healthcare workers to give targeted treatment. 

Empowering Healthcare Workers: With minimal training, technicians or Community Health Extension Workers (CHEWs) can operate the device, expanding diagnostic capacity in resource-limited settings.

In addition to Severe Malaria detection, we are advancing the development of similar AI applications using the same device to facilitate the early, affordable detection of diabetic and hypertensive retinopathies in patients with Diabetes and Hypertension.

We are seeking partnerships with payers — including federal and state governments, donor agencies, and private sector organizations — to implement ASPIRE across secondary and tertiary hospitals. Aligned with our theory of change framework, we project that ASPIRE can reduce malaria mortality by 20% within 18 months of implementation.

Thank you for considering this opportunity. I would be delighted to discuss further how we can collaborate to bring ASPIRE to facilities in need.